BYSI News and Press, BeyondSpring Inc. From 09/11/20

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet med...

BeyondSpring (NASDAQ: BYSI )   +9.5%  in premarket as the FDA and China’s Center for Drug Evaluation  designates the company's Plinabulin as a Breakthrough Therapy for the treatment of chemotherapy-induced neutropenia (CIN). More news on: BeyondSpring...

- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) - - Designation Based on PROTECTIVE-2 Phas...

Image source: The Motley Fool. BeyondSpring Inc.   (NASDAQ: BYSI) Q2 2020 Earnings Call Sep 3, 2020 , 8:00 a.m. ET Operator Continue reading

BeyondSpring Inc. (BYSI) Q2 2020 Earnings Conference Call September 3, 2020 8:00 A.M. ET Company Participants Scott Eckstein - Vice President at KCSA Strategic Communications Lan Huang - Co-Founder, Chairman and Chief Executive Officer Ramon Mohanlal - Executive Vice President, R...

BeyondSpring (NASDAQ: BYSI ) : Q2 GAAP EPS of -$0.46  beats by $0.11 . More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta Alone- - Completed PROTECTIVE-2 Phase 3 Enrollment and On Track to Report Final R...

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-q...

Our analysis concludes the share prices of oncology-related companies are down, on average, 25% from peaking the third week of June 2020. With the exception of Agenus Inc. ( AGEN ), that appears to be trading higher on anticipation its vaccine adjuvant will be used in 2 or more of the eventual...

NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has ap...